Literature DB >> 10903474

Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter.

M Hernandez1, J Montenegro, M Steiner, D Kim, C Sparrow, P A Detmers, S D Wright, Y S Chao.   

Abstract

Although the mechanism by which dietary cholesterol is absorbed from the intestine is poorly understood, it is generally accepted that cholesterol is absorbed from bile acid micelles in the jejunum. Once inside the enterocytes, cholesterol is esterified by the action of acyl-coenzyme A:cholesterol acyltransferase (ACAT), assembled into chylomicrons, and secreted into the lymph. In this work, mechanistic aspects of cholesterol absorption were probed using compounds that block cholesterol absorption in hamsters. Sterol glycoside cholesterol absorption inhibitors, exemplified by L-166,143, (3 beta, 5 alpha,25R)-3-[(4", 6"-bis[2-fluoro-phenylcarbamoyl]-B-D-cellobiosyl)oxy]-spirostan -11-on e, potently blocked absorption of radioactive cholesterol, and the potencies of several analogs correlated with their ability to lower plasma cholesterol. Each molecule of L-166,143 blocked the uptake of 500 molecules of cholesterol, rendering it unlikely that the inhibitor interacts directly with the cholesterol or bile acid. Radiolabeled L-166,143 bound to the mucosa and binding was blocked by active, but not inactive, cholesterol absorption inhibitors. Subtle changes in the structure of sterol glycosides yielded large changes in their ability to block both cholesterol absorption and binding of radiolabeled L-166,143. Large species-to-species variation in potency was also observed. These lines of evidence support the interpretation that dietary cholesterol is absorbed via a specific transporter found in the intestinal mucosa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903474     DOI: 10.1016/s1388-1981(00)00067-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Small bowel review: Normal physiology, part 1.

Authors:  Alan B R Thomson; Laurie Drozdowski; Claudiu Iordache; Ben K A Thomson; Severine Vermeire; M Tom Clandinin; Gary Wild
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

2.  Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.

Authors:  Tomás Zambrano; Nicolás Saavedra; Fernando Lanas; José Caamaño; Luis A Salazar
Journal:  Mol Diagn Ther       Date:  2015-02       Impact factor: 4.074

Review 3.  Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs.

Authors:  Carlos Leon; John S Hill; Kishor M Wasan
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

Review 4.  Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways.

Authors:  Shailendra B Patel
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

5.  Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats.

Authors:  Margaret van Heek; Constance Farley; Douglas S Compton; Lizbeth M Hoos; April Smith-Torhan; Harry R Davis
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.